SARS CoV 2 News and Research

RSS

Wuhan coronavirus is genetically different from human SARS, MERS-CoV, study found

The Wuhan coronavirus or the 2019-nCoV or novel coronavirus is a new human-infecting coronavirus genetically different from human SARS (Severe Acute Respiratory Syndrome), and MERS-CoV (Middle East Respiratory Syndrome), a team of scientists has found.

30 Jan 2020

Coronavirus could turn into a new pandemic

With news that the coronavirus called 2019-nCoV is capable of spreading from human to human, many are concerned about the possibility of a new pandemic, and that is not outside the realm of possibility, according to Jeff Hogan, a professor and infectious disease expert at the University of Georgia, who studied the SARS coronavirus extensively.

24 Jan 2020

NIAID officials describe steps to control coronavirus that recently originated in China

The new cluster of viral pneumonia cases originating in Wuhan, China, marks the third time in 20 years that a member of the large family of coronaviruses (CoVs) has jumped from animals to humans and sparked an outbreak.

24 Jan 2020

Study: New SARS-like WIV1-CoV virus poised to infect humans

A SARS-like virus found in Chinese horseshoe bats may be poised to infect humans without the need for adaptation, overcoming an initial barrier that could potentially set the stage for an outbreak according to a study at the University of North Carolina at Chapel Hill.

16 Mar 2016

Cryo-electron microscopy helps analyze infection mechanisms of coronaviruses in detail

High-resolution cryo-electron microscopy and supercomputing have now made it possible to analyze in detail the infection mechanisms of coronaviruses. These viruses are notorious for attacking the respiratory tract of humans and animals.

27 Feb 2016

Researchers identify existing drugs that could be "repurposed" to fight MERS-CoV

A team led by a University of Maryland School of Medicine (UM SOM) researcher, working as a grantee from the National Institutes of Health (NIH), has identified a number of existing drugs that could be "repurposed" to fight outbreaks of Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).

22 May 2014

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

20 May 2014

Scientists identify natural human antibodies against virus that causes MERS

Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.

29 Apr 2014

EcoHealth Alliance discovers new SARS-like coronavirus in Chinese horseshoe bats

EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, announced the discovery of a new SARS-like coronavirus (CoV) in Chinese horseshoe bats.

31 Oct 2013

Study: lncRNA are involved in host response to viral infection

Scientists have demonstrated for the first time that a certain class of RNA (known as long non-protein-coding RNA [lncRNA]) are involved in the host response to viral infection. These findings, published today in the online journal mBio-, could greatly change the way scientists look at the body's response to viral infection.

27 Oct 2010

Long non-protein coding RNAs respond to SARS virus infection, says study

For the first time, scientists have discovered that a poorly understood class of RNA produced in a mammal's cells during a respiratory virus attack may affect the outcome of the infection. Their findings are reported today in mBio, a journal of the American Society for Microbiology.

27 Oct 2010

Genomics can provide insights in understanding emerging infectious disease

This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.

27 Oct 2009

Algae may the key to SARS vaccine

A protein from algae may have what it takes to stop Severe Acute Respiratory Syndrome (SARS) infections, according to new research.

20 May 2009

Researchers generate synthetic SARS-like bat coronavirus

SARS - severe acute respiratory syndrome - alarmed the world five years ago as the first global pandemic of the 21st century.

25 Nov 2008

Scientists reconstruct bat variant of SARS coronavirus

Researchers at the University of North Carolina at Chapel Hill and Vanderbilt University Medical Center have synthetically reconstructed the bat variant of the SARS coronavirus (CoV) that caused the SARS epidemic of 2003.

25 Nov 2008

Evidence supports bats as SARS virus source

Scientists who have studied the genome of the virus that caused severe acute respiratory syndrome (SARS) say their comparisons to related viruses offer new evidence that the virus infecting humans originated in bats.

20 Feb 2008

Flu medication VIRA 38 inhibits SARS virus

PRB Pharmaceuticals and Lee's Pharmaceuticals have announced that a recent study by Taiwan researchers from the National Health Research Institutes demonstrates TF2b and TF3, two components of v38 AMF-1, inhibit the 3C-like protease encoded by SARS-CoV. v38 AMF-1, a fraction of the flu medication VIRA 38, is best known for its ability to inhibit bird flu virus (H5N1) infections.

4 Aug 2005

SARS vaccine produced from plants

According to new research, a vaccine has been produced in genetically engineered tomato and tobacco plants, which triggers anti-SARS antibodies in mice.

15 Jun 2005

New glycan arrays discover autoimmunogenic activities of SARS-CoV

Researchers in New York City and Guangzhou, China applied the rapidly-developing carbohydrate microarray technology to study an inactivated SARS-coronavirus (SARS-CoV) vaccine and discovered autoimmunogenic activity of this newly identified human viral pathogen.

2 Aug 2004

SARS siRNA studied further to help many respiratory diseases including lung cancer

Intradigm Corporation, has announced achievement of prophylactic and therapeutic effects of siRNA (small interfering RNA) inhibitors of SARS-CoV in non-human primate cells. The results are published in the June 2004 issue of Antiviral Therapy (International Medical Press).

15 Jun 2004